 treatment gram-neg bacteremia septic shock human monoclon antibodi endotoxin random double-blind placebo-control trial sepsi studi group background human monoclon igm antibodi lipid domain endotoxin prevent death laboratori anim gram-neg bacteremia endotoxemia method efficaci safeti double-blind trial patient sepsi presum diagnosi gram-neg infect patient singl intraven dose albumin placebo albumin other intervent administr antibiot fluid studi protocol result patient sepsi percent gram-neg bacteremia blood cultur patient gram-neg bacteremia death day death recipi placebo percent death recipi percent patient gram-neg bacteremia shock entri death recipi placebo percent death recipi percent sever ill entri improv surviv treatment ill ill patient patient gram-neg bacteremia discharg death placebo percent aliv percent benefit treatment patient sepsi gram-neg bacteremia patient sepsi mortal rate percent recipi placebo percent patient antibodi conclus safe effect treatment patient sepsi gram-neg bacteremia